Cynthia K. Wallace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cynthia K. Wallace has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Allison Thibodeau
Fred Hutchinson Cancer Center
1 shared publication Catherine Liu
Fred Hutchinson Cancer Center
1 shared publicationElizabeth M. Krantz
Fred Hutchinson Cancer Center
1 shared publication- Emily A. Rosen
Fred Hutchinson Cancer Center
1 shared publication Joanne Lang
University of Washington
1 shared publication- Joyce Pang
Swedish Colon & Rectal Clinic Edmonds Washington USA
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e368
Yield of a multiplexed gastrointestinal polymerase chain reaction panel for evaluation of diarrhea in hospitalized patients with cancer: a diagnostic stewardship opportunity
Background: Multiplexed polymerase chain reaction gastrointestinal panels (GIPs) include mostly community-acquired pathogens. Diagnostic yield of GIPs for detection of non- Clostridioides difficile targets in hospitalized patients with cancer with community versus hospital-onset diarrhea is not well defined. Methods: This cross-sectional study included stool tests from hospitalized adults with a cancer diagnosis from July 2021 to May 2025. Our center recommends a GIP primarily for patients with community-onset diarrhea and stand-alone C. difficile testing for hospital-onset diarrhea. Generalized estimating equations with Poisson regression were used to estimate the prevalence ratio (PR) of detecting ≥1 non- C. difficile target after hospital day (HD) 3 compared to HD 1–3. Results: Among 1,433 GIPs from 1,127 patients, 468 (33%) were ordered after HD 3. Most GIPs were among patients with hematologic malignancies (794/1,433; 55%) and of those tests 352/794 (44%) were ordered after HD 3. Among all GIPs, C. difficile and norovirus were detected most frequently (16% and 6%, respectively). A non- C. difficile target was detected after HD 3 on 49/468 GIPs (10%), compared to 146/965 (15%) GIPs on HD 1–3 (adjusted PR 0.73; 95% CI [0.53–1.00]; P = .053). Among 49 GIPs after HD 3 detecting ≥1 non- C. difficile target, 19 tests were ordered for new-onset diarrhea and only 5 of these patients received intentional antimicrobial therapy in response to the GIP result. Conclusions: The added diagnostic yield for detecting ≥1 non- C. difficile target by GIP in patients with cancer and hospital-onset diarrhea is limited and supports restricting GIP ordering after HD 3 on oncology units.
- 12 November 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e368
Open AccessYield of a multiplexed gastrointestinal polymerase chain reaction panel for evaluation of diarrhea in hospitalized patients with cancer: a diagnostic stewardship opportunity
Background: Multiplexed polymerase chain reaction gastrointestinal panels (GIPs) include mostly community-acquired pathogens. Diagnostic yield of GIPs for detection of non- Clostridioides difficile targets in hospitalized patients with cancer with community versus hospital-onset diarrhea is not well defined. Methods: This cross-sectional study included stool tests from hospitalized adults with a cancer diagnosis from July 2021 to May 2025. Our center recommends a GIP primarily for patients with community-onset diarrhea and stand-alone C. difficile testing for hospital-onset diarrhea. Generalized estimating equations with Poisson regression were used to estimate the prevalence ratio (PR) of detecting ≥1 non- C. difficile target after hospital day (HD) 3 compared to HD 1–3. Results: Among 1,433 GIPs from 1,127 patients, 468 (33%) were ordered after HD 3. Most GIPs were among patients with hematologic malignancies (794/1,433; 55%) and of those tests 352/794 (44%) were ordered after HD 3. Among all GIPs, C. difficile and norovirus were detected most frequently (16% and 6%, respectively). A non- C. difficile target was detected after HD 3 on 49/468 GIPs (10%), compared to 146/965 (15%) GIPs on HD 1–3 (adjusted PR 0.73; 95% CI [0.53–1.00]; P = .053). Among 49 GIPs after HD 3 detecting ≥1 non- C. difficile target, 19 tests were ordered for new-onset diarrhea and only 5 of these patients received intentional antimicrobial therapy in response to the GIP result. Conclusions: The added diagnostic yield for detecting ≥1 non- C. difficile target by GIP in patients with cancer and hospital-onset diarrhea is limited and supports restricting GIP ordering after HD 3 on oncology units.
- 3 August 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70291
An Unusual Perianal Lesion: Host Defenses Gone Awry
- 3 August 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70291
An Unusual Perianal Lesion: Host Defenses Gone Awry